A phase 2 study of fianlimab (anti–LAG-3) plus cemiplimab (anti–PD-1) versus cemiplimab plus placebo in patients with recurrent/metastatic head and neck squamous cell carcinoma (HNSCC) with positive PD-L1 expression.

Authors: Danny Rischin, Paolo Bossi, Nabil F. Saba, Tanguy Y. Seiwert, Deborah J.L. Wong, Qiong Zhao, Shikha Bansal, Mark Salvati, Israel Lowy, Matthew G. Fury, Ahmed Khaled

Published: 2025-05-28

DOI: 10.1200/jco.2025.43.16_suppl.tps6112

Source: Full article

---

Abstract

TPS6112